Dual inhibition of mTORC1/C2 and HER2 results in maximal antitumor efficacy in preclinical model of HER2+breast cancer resistant to trastuzumab therapy

被引：1
|
作者：
De, Pradip Kr [1 ]
Sun, Yuliang [1 ]
Carlson, Jennifer H. [1 ]
Lin, Xiaoqian [1 ]
Dey, Nandini [1 ]
Leyland-Jones, Brian [1 ]
机构：
[1] Avera Res Inst, Sioux Falls, SD USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1940
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1940
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Primary systemic therapy by dual HER2 blockage with lapatinib (La) plus trastuzumab (T) for Japanese patients (pts) with HER2+breast cancer (BC): Association of La toxicity and dose with treatment efficacy
    Yamashita, T.
    Masuda, N.
    Yamamoto, N.
    Kondo, N.
    Bando, H.
    Akiyoshi, S.
    Ohtani, S.
    Takano, T.
    Inoue, K.
    Fujisawa, T.
    Ishiguro, H.
    Nakayama, H.
    Aogi, K.
    Amano, S.
    Ozaki, H.
    Yasojima, H.
    Kasai, H.
    Kataoka, T. R.
    Morita, S.
    Toi, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S317 - S318
  • [32] Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
    Giulia Bon
    Laura Pizzuti
    Valentina Laquintana
    Rossella Loria
    Manuela Porru
    Caterina Marchiò
    Eriseld Krasniqi
    Maddalena Barba
    Marcello Maugeri-Saccà
    Teresa Gamucci
    Rossana Berardi
    Lorenzo Livi
    Corrado Ficorella
    Clara Natoli
    Enrico Cortesi
    Daniele Generali
    Nicla La Verde
    Alessandra Cassano
    Emilio Bria
    Luca Moscetti
    Andrea Michelotti
    Vincenzo Adamo
    Claudio Zamagni
    Giuseppe Tonini
    Giacomo Barchiesi
    Marco Mazzotta
    Daniele Marinelli
    Silverio Tomao
    Paolo Marchetti
    Maria Rosaria Valerio
    Rosanna Mirabelli
    Antonio Russo
    Maria Agnese Fabbri
    Nicola D’Ostilio
    Enzo Veltri
    Domenico Corsi
    Ornella Garrone
    Ida Paris
    Giuseppina Sarobba
    Francesco Giotta
    Carlo Garufi
    Marina Cazzaniga
    Pietro Del Medico
    Mario Roselli
    Giuseppe Sanguineti
    Isabella Sperduti
    Anna Sapino
    Ruggero De Maria
    Carlo Leonetti
    Angelo Di Leo
    Journal of Experimental & Clinical Cancer Research, 39
  • [33] Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
    Bon, Giulia
    Pizzuti, Laura
    Laquintana, Valentina
    Loria, Rossella
    Porru, Manuela
    Marchio, Caterina
    Krasniqi, Eriseld
    Barba, Maddalena
    Maugeri-Sacca, Marcello
    Gamucci, Teresa
    Berardi, Rossana
    Livi, Lorenzo
    Ficorella, Corrado
    Natoli, Clara
    Cortesi, Enrico
    Generali, Daniele
    La Verde, Nicla
    Cassano, Alessandra
    Bria, Emilio
    Moscetti, Luca
    Michelotti, Andrea
    Adamo, Vincenzo
    Zamagni, Claudio
    Tonini, Giuseppe
    Barchiesi, Giacomo
    Mazzotta, Marco
    Marinelli, Daniele
    Tomao, Silverio
    Marchetti, Paolo
    Valerio, Maria Rosaria
    Mirabelli, Rosanna
    Russo, Antonio
    Fabbri, Maria Agnese
    D'Ostilio, Nicola
    Veltri, Enzo
    Corsi, Domenico
    Garrone, Ornella
    Paris, Ida
    Sarobba, Giuseppina
    Giotta, Francesco
    Garufi, Carlo
    Cazzaniga, Marina
    Del Medico, Pietro
    Roselli, Mario
    Sanguineti, Giuseppe
    Sperduti, Isabella
    Sapino, Anna
    De Maria, Ruggero
    Leonetti, Carlo
    Di Leo, Angelo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [34] Dual inhibition of FGFR4 and HER2/EGFR with Lapatinib improves targeting of Erk and Akt signaling in HER2+breast cancer cells
    Beardsley, Jordan
    Goode, Joseph
    Altomare, Deborah
    CANCER RESEARCH, 2024, 84 (09)
  • [35] mTORC1 Activity Contributes to the Mcl-1 Dependence of HER2 Amplified Breast Cancer Cells
    Campone, M.
    Noel, B.
    Gouraud, W.
    Jezequel, P.
    Barille-Nion, S.
    Juin, P.
    CANCER RESEARCH, 2009, 69 (24) : 644S - 644S
  • [36] Optimizing combination therapy in a murine model of HER2+breast cancer?
    Lima, Ernesto A. B. F.
    Wyde, Reid A. F.
    Sorace, Anna G.
    Yankeelov, Thomas E.
    COMPUTER METHODS IN APPLIED MECHANICS AND ENGINEERING, 2022, 402
  • [37] Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma
    Jiang, Haibin
    Zeng, Zhiyuan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 468 (1-2) : 255 - 261
  • [38] Early results of combined Her-2/neu (HER2) immunotherapy using a HER2 peptide vaccine with concurrent trastuzumab for metastatic breast cancer.
    Webster, D.
    Waisman, J.
    MacLeod, B.
    dela Rosa, C.
    Higgins, D.
    Fintak, P.
    Childs, J.
    Slota, M.
    Salazar, L.
    Disis, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S79 - S80
  • [39] Her2 Status Following Neoadjuvant Trastuzumab Therapy for Primary Breast Cancer
    Sanders, M. A. G.
    Richardson, A. L.
    Ly, A.
    MODERN PATHOLOGY, 2011, 24 : 62A - 62A
  • [40] Her2 Status Following Neoadjuvant Trastuzumab Therapy for Primary Breast Cancer
    Sanders, M. A. G.
    Richardson, A. L.
    Ly, A.
    LABORATORY INVESTIGATION, 2011, 91 : 62A - 62A
12345